|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #redirect [[Simvastatin#Adult Indications and Dosage]] |
| {{Simvastatin}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Dosage and Administration==
| |
| | |
| ===Recommended Dosing===
| |
| | |
| The usual dosage range is 5 to 40 mg/day. In patients with CHD or at high risk of CHD, ZOCOR can be started simultaneously with diet. The recommended usual starting dose is 10 or 20 mg once a day in the evening. For patients at high risk for a CHD event due to existing CHD, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease, the recommended starting dose is 40 mg/day. Lipid determinations should be performed after 4 weeks of therapy and periodically thereafter.
| |
| | |
| ===Restricted Dosing for 80 mg===
| |
| | |
| Due to the increased risk of [[myopathy]], including [[rhabdomyolysis]], particularly during the first year of treatment, use of the 80-mg dose of ZOCOR should be restricted to patients who have been taking simvastatin 80 mg chronically (e.g., for 12 months or more) without evidence of muscle toxicity [see Warnings and Precautions (5.1)].
| |
| | |
| Patients who are currently tolerating the 80-mg dose of ZOCOR who need to be initiated on an interacting drug that is contraindicated or is associated with a dose cap for simvastatin should be switched to an alternative [[statin]] with less potential for the drug-drug interaction.
| |
| | |
| Due to the increased risk of [[myopathy]], including [[rhabdomyolysis]], associated with the 80-mg dose of ZOCOR, patients unable to achieve their LDL-C goal utilizing the 40-mg dose of ZOCOR should not be titrated to the 80-mg dose, but should be placed on alternative LDL-C-lowering treatment(s) that provides greater LDL-C lowering.
| |
| | |
| ===Coadministration with Other Drugs===
| |
| | |
| Patients taking [[Verapamil]], [[Diltiazem]], or [[Dronedarone]]
| |
| | |
| The dose of ZOCOR should not exceed 10 mg/day [see Warnings and Precautions (5.1), Drug Interactions (7.3), and Clinical Pharmacology (12.3)].
| |
| | |
| Patients taking [[Amiodarone]], [[Amlodipine]] or [[Ranolazine]]
| |
| | |
| The dose of ZOCOR should not exceed 20 mg/day [see Warnings and Precautions (5.1), Drug Interactions (7.3), and Clinical Pharmacology (12.3)].
| |
| | |
| ===Patients with Homozygous Familial Hypercholesterolemia===
| |
| | |
| The recommended dosage is 40 mg/day in the evening [see Dosage and Administration, Restricted Dosing for 80 mg (2.2)]. ZOCOR should be used as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) in these patients or if such treatments are unavailable.
| |
| | |
| Simvastatin exposure is approximately doubled with concomitant use of [[lomitapide]]; therefore, the dose of ZOCOR should be reduced by 50% if initiating [[lomitapide]]. ZOCOR dosage should not exceed 20 mg/day (or 40 mg/day for patients who have previously taken ZOCOR 80 mg/day chronically, e.g., for 12 months or more, without evidence of muscle toxicity) while taking [[lomitapide]].
| |
| | |
| ===Adolescents (10-17 years of age) with Heterozygous Familial Hypercholesterolemia===
| |
| | |
| The recommended usual starting dose is 10 mg once a day in the evening. The recommended dosing range is 10 to 40 mg/day; the maximum recommended dose is 40 mg/day. Doses should be individualized according to the recommended goal of therapy [see NCEP Pediatric Panel Guidelines2 and Clinical Studies (14.2)]. Adjustments should be made at intervals of 4 weeks or more.
| |
| | |
| <sup>2</sup>
| |
| | |
| <small><small><small>National Cholesterol Education Program (NCEP): Highlights of the Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents.Pediatrics. 89(3):495-501. 1992.</small></small></small>
| |
| ===Patients with Renal Impairment===
| |
| | |
| Because ZOCOR does not undergo significant renal excretion, modification of dosage should not be necessary in patients with mild to moderate renal impairment. However, caution should be exercised when ZOCOR is administered to patients with severe renal impairment; such patients should be started at 5 mg/day and be closely monitored [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].
| |
| | |
| ===Chinese Patients Taking Lipid-Modifying Doses (≥1 g/day Niacin) of Niacin-Containing Products===
| |
| | |
| Because of an increased risk for [[myopathy]] in Chinese patients taking simvastatin 40 mg coadministered with lipid-modifying doses (≥1 g/day niacin) of [[niacin]]-containing products, caution should be used when treating Chinese patients with simvastatin doses exceeding 20 mg/day coadministered with lipid-modifying doses of [[niacin]]-containing products. Because the risk for [[myopathy]] is dose-related, Chinese patients should not receive simvastatin 80 mg coadministered with lipid-modifying doses of [[niacin]]-containing products. The cause of the increased risk of [[myopathy]] is not known. It is also unknown if the risk for [[myopathy]] with coadministration of simvastatin with lipid-modifying doses of [[niacin]]-containing products observed in Chinese patients applies to other Asian patients. [See Warnings and Precautions (5.1).]<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ZOCOR (SIMVASTATIN) TABLET, FILM COATED [MERCK SHARP & DOHME CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fdbfe194-b845-42c5-bb87-a48118bc72e7 | publisher = | date = | accessdate = 18 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist|2}}
| |
| | |
| {{Statins}}
| |
| {{Merck&Co}}
| |
|
| |
|
| [[Category:Alcohols]] | | [[Category:Alcohols]] |